Principal investigator Dr Mikhail Kosiborod, of Saint Luke's Mid-America Heart Institute in Kansas City, said: "To our knowledge, this is the first trial of a pharmacologic agent to specifically target obesity as a treatment strategy for HFpEF, and the magnitude of the benefits we observed is the largest seen with any agent in HFpEF." He added: "This will likely have a significant impact on clinical practice, especially since there is a dearth of efficacious therapies in this vulnerable patient group." He also said that the findings should spark a change in the way obesity in people with heart failure is viewed, suggesting that, in HFpEF at least, "obesity is not simply a comorbidity in patients with HFpEF, but a root cause and a target for therapeutic intervention." The data provides another compelling endorsement for semaglutide, which is at the head of a series of new obesity therapies addressing GLP-1 and other targets, and keeps Novo Nordisk's drug ahead of challengers like Eli Lilly's combined GLP-1/GIP agonist Mounjaro (tirzepatide)
[8] Keegan, S
WHAT IS CJC-1295
How clinicians currently interpret the evidence Clinicians balance the low frequency of serious events in population data with scattered individual reports of intolerance
The simple truth If it isn't coming from a legitimate clinic/pharmacy route, you cannot reliably know: what's in it, how strong it is, whether it was stored correctly, whether it's sterile
